Gulf Coast

Gulf Coast Midstream Partners secured investment from Black Bay Partners to advance a natural gas storage hub in Southeast Texas

Gulf Coast Midstream Partners Secures Investment from Black Bay Partners to Advance the Development of Natural Gas Storage Hub in Southeast Texas Gulf Coast Midstream Partners, LLC a private developer of energy midstream assets, today announced a growth capital investment…

Read MoreGulf Coast Midstream Partners secured investment from Black Bay Partners to advance a natural gas storage hub in Southeast Texas
Cloud Range

Cloud Range won Gold in the 2026 Cybersecurity Excellence Awards for cyber readiness and validation

Cloud Range Wins Gold in 2026 Cybersecurity Excellence Awards for Cyber Readiness and Validation Cloud Range, the industry-leading cyber readiness and simulation platform, has been named a Gold Award recipient in the Cyber Readiness and Validation category of the 2026…

Read MoreCloud Range won Gold in the 2026 Cybersecurity Excellence Awards for cyber readiness and validation
CatalYm

CatalYm has dosed the first patient in a Phase 2b trial of visugromab with chemoimmunotherapy for advanced liver cancer

CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma CatalYm announced that the first patient has been dosed in the GDFATHER-HCC-01 trial The trial evaluates the company’s lead anti-GDF-15…

Read MoreCatalYm has dosed the first patient in a Phase 2b trial of visugromab with chemoimmunotherapy for advanced liver cancer

Pulse Biosciences has enrolled the first patients in its pivotal NANOPULSE-AF study evaluating the nPulse™ system for atrial fibrillation

Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Pulse Biosciences, Inc. developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced enrollment of the first…

Read MorePulse Biosciences has enrolled the first patients in its pivotal NANOPULSE-AF study evaluating the nPulse™ system for atrial fibrillation
Ducon

Ducon Unveils Advanced Technologies to Reduce Air Pollution Caused by Missile Interceptions

Ducon Announces Advanced Solutions to Mitigate Air Pollution from Missile Interceptions Ducon Technologies a global leader in high-efficiency air pollution control and infrastructure related technologies, announced solutions for the escalating environmental and public health crisis caused by high-altitude missile interceptions…

Read MoreDucon Unveils Advanced Technologies to Reduce Air Pollution Caused by Missile Interceptions
Aspect

Aspect Biosystems announces a $280 million partnership with the Government of Canada to advance bioengineered cell therapies

Aspect Biosystems Announces $280 Million Partnership with Government of Canada to Advance Development of Bioengineered Cellular Medicines Aspect Biosystems, a biotechnology company pioneering a novel category of regenerative medicine, today announced that it has received a $79 million investment from…

Read MoreAspect Biosystems announces a $280 million partnership with the Government of Canada to advance bioengineered cell therapies
Swaney

Swaney Group Capital and LongueVue Capital invest in Apex Dental Laboratory Group

Swaney Group Capital and LongueVue Capital Invest in Apex Dental Laboratory Group Swaney Group Capital a Tampa-based private equity firm, in partnership with LongueVue Capital a New Orleans-based private equity firm, announced a strategic investment in Apex Dental Laboratory Group (“Apex”…

Read MoreSwaney Group Capital and LongueVue Capital invest in Apex Dental Laboratory Group
CTIS

CTIS, Inc. Launches Trial SafetyXchange to Help Pharma Companies Meet Critical FDA E2B(R3) Compliance Deadline

CTIS, Inc. Launches Trial SafetyXchange to Help Pharma Companies Meet Critical FDA E2B(R3) Compliance Deadline CTIS, Inc., with more than 30 years of experience in Health IT and clinical research informatics expertise for government and industry clients, today announced the…

Read MoreCTIS, Inc. Launches Trial SafetyXchange to Help Pharma Companies Meet Critical FDA E2B(R3) Compliance Deadline
Aspect

Harmony Biosciences enhances its executive team and expands its board with new appointments

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board Harmony Biosciences Holdings, Inc. announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy…

Read MoreHarmony Biosciences enhances its executive team and expands its board with new appointments
Clarametyx

Clarametyx Biosciences bolsters its leadership team to speed up clinical development.

Clarametyx Biosciences Strengthens Executive Leadership to Accelerate Clinical Development Efforts Clarametyx Biosciences, Inc. a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory disease, today announced two senior leadership positions within its executive team to support…

Read MoreClarametyx Biosciences bolsters its leadership team to speed up clinical development.
Coya Therapeutics

Coya Therapeutics announced a board transition and appointed Mark H. Pavao as an independent director

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director Coya Therapeutics, Inc. a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that founder Howard Berman,…

Read MoreCoya Therapeutics announced a board transition and appointed Mark H. Pavao as an independent director